|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
Our results therefore implicate SIP1 in the regulation of vimentin observed in the EMT associated with breast tumor cell migration, a pathway that may contribute to the metastatic progression of breast cancer.
|
16568083 |
2006 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
Since vimentin and laminin staining is widely used by pathologists for diagnostic purposes, thus demonstrating the robustness of their specific antibodies, the immunohistochemical evaluation of these two molecules could be used in identification of basal-like breast tumours in both sporadic/familial cases.
|
17105822 |
2007 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
This is mainly supported by the significantly higher incidence of vimentin-expressing breast cancers compared to any other myoepithelial breast tumours and the fact that vimentin is already observed in ductal in situ components.
|
15906273 |
2005 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
Treatments of human non-tumorigenic mammary epithelial and breast tumor cells with Lidocaine or Tetracaine caused rapid collapse of vimentin filaments.
|
21069453 |
2011 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
LHGDN |
Our results therefore implicate SIP1 in the regulation of vimentin observed in the EMT associated with breast tumor cell migration, a pathway that may contribute to the metastatic progression of breast cancer.
|
16568083 |
2006 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
CTD_human |
MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
|
24014025 |
2013 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
|
Mammary Neoplasms
|
0.380 |
PosttranslationalModification
|
group |
BEFREE |
We therefore quantified Vimentin DNA methylation using MALDI-TOF mass spectrometry in breast tumors and matched normal pairs in association with gene expression and survival in a hospital-based study of breast cancer patients.
|
23239149 |
2013 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
CTD_human |
Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.
|
27811057 |
2016 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
LHGDN |
Transactivation of vimentin by beta-catenin in human breast cancer cells.
|
12750294 |
2003 |
|
Mammary Neoplasms
|
0.380 |
AlteredExpression
|
group |
LHGDN |
Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion.
|
17585878 |
2007 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
Here, we show that human breast tumor biomarker miR-30c regulates invasion by targeting the cytoskeleton network genes encoding twinfilin 1 (TWF1) and vimentin (VIM).
|
23224145 |
2013 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
BEFREE |
Interestingly, ADT also induced high levels of vimentin expression in prostate cancer cell lines in vitro and in human prostate tumors in vivo.
|
21677876 |
2011 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
CTD_human |
Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.
|
17566973 |
2007 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
LHGDN |
Vimentin affects the mobility and invasiveness of prostate cancer cells.
|
18464297 |
2008 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
LHGDN |
Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer.
|
12727854 |
2003 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo.
|
19276168 |
2009 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
CTD_human |
The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.
|
24763052 |
2014 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
BEFREE |
Expression profiling and localization for EMT effectors, E-Cadherin, N-Cadherin, β-catenin and Vimentin was assessed in human prostate tumor specimens pre- and post-radiotherapy and correlated with biochemical recurrence.
|
29063620 |
2017 |
|
Peritoneal Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features.
|
22784439 |
2013 |
|
Retinal Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Resveratrol mitigates rat retinal ischemic injury: the roles of matrix metalloproteinase-9, inducible nitric oxide, and heme oxygenase-1.
|
23075401 |
2013 |
|
Degenerative Diseases, Central Nervous System
|
0.300 |
Biomarker
|
group |
CTD_human |
Cell death pathways differ in several mouse models with motoneurone disease: analysis of pure motoneurone populations at a presymptomatic age.
|
16831193 |
2006 |
|
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Cell death pathways differ in several mouse models with motoneurone disease: analysis of pure motoneurone populations at a presymptomatic age.
|
16831193 |
2006 |
|
Degenerative Diseases, Spinal Cord
|
0.300 |
Biomarker
|
group |
CTD_human |
Cell death pathways differ in several mouse models with motoneurone disease: analysis of pure motoneurone populations at a presymptomatic age.
|
16831193 |
2006 |